Jasper Therapeutics, Inc.
0.0M
$0.35M
-0.46
$-3.95
No price alerts set. Add an alert to get notified!
-0.46
8.45
$-3.95
-1,826.09%
0.00%
0.00%
Compare TSM with similar companies in the sector
| Company | Price | Change % | P/E | Market Cap | D/E |
|---|---|---|---|---|---|
|
AZTR
Azitra, Inc.
|
$0.23 | -0.47% | -0.10 | $2.51M | 0.16 |
|
ENVB
Enveric Biosciences, Inc.
|
$2.04 | 4.08% | -0.25 | $1.22M | 0.00 |
|
INDP
Indaptus Therapeutics, Inc.
|
$1.85 | 17.83% | -0.19 | $3.24M | 0.00 |
|
ONCO
Onconetix, Inc.
|
$1.18 | 4.42% | -0.28 | $4.04M | 0.00 |
|
PTIX
Protagenic Therapeutics, Inc.
|
$0.69 | 30.19% | -0.26 | $1.34M | -1.32 |
|
REVB
Revelation Biosciences, Inc.
|
$1.23 | 1.65% | -0.86 | $1.82M | 0.08 |
|
SCNI
Scinai Immunotherapeutics Ltd.
|
$0.59 | 1.79% | -0.09 | $776,593 | 0.28 |
|
SLRX
Salarius Pharmaceuticals, Inc.
|
$0.84 | 29.23% | -0.23 | $4.92M | 0.00 |
|
SLXN
Silexion Therapeutics Ltd.
|
$1.11 | -0.89% | -0.29 | $622,670 | 0.18 |
|
SPRC
SciSparc Ltd.
|
$3.06 | -10.53% | -0.01 | $176,987 | -3.14 |
* Peer stocks are selected based on market capitalization and sector
$0.08
$0.02
$0.00
0.00%
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.
